Multimodal Treatment of Metastatic Adrenal Cortical Carcinoma: Clinical Case and Proposed Comprehensive Strategy in Colombia

Tratamiento multimodal de carcinoma adrenocortical metastásico: caso clínico y propuesta de estrategia integral en Colombia

Published 2024-12-05

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 11 No. 2 (2024): Julio - Diciembre
Section
Clinic cases
How to Cite
Multimodal Treatment of Metastatic Adrenal Cortical Carcinoma: Clinical Case and Proposed Comprehensive Strategy in Colombia.
Rev. colomb. hematol. oncol. [Internet]. 2024 Dec. 5 [cited 2024 Dec. 22];11(2):93-102. Disponible en: https://doi.org/10.51643/22562915.699
DOI

https://doi.org/10.51643/22562915.699
Dimensions
PlumX
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Lucy Maritza Pérez Lugo
Fundación Valle del Lili , Universidad ICESI, Cali, Colombia image/svg+xml
    https://orcid.org/0009-0002-8440-0361
    Álvaro Enrique Osorio Franco
    Fundación Valle del Lili , Cali, Colombia. image/svg+xml
      Show authors biography

      Lucy Maritza Pérez Lugo,

      Médica internista, Fellow de Hematología y Oncología. Fundación Valle de Lili y Universidad ICESI.

      Álvaro Enrique Osorio Franco,

      Médico internista, Hematólogo y Oncólogo. Fundación Valle de Lili.

      The frequency of adrenal tumors is high, affecting 3-10% of the population. In contrast, adrenocortical carcinoma is a rare disease with an estimated incidence of 0.7 cases per million per year. In most patients with adrenocortical carcinoma, hormonal overproduction can be demonstrated, with Cushing's syndrome being the most commonly associated clinical presentation. There is limited evidence regarding the optimal treatment for this condition. Clinical case: We present the case of a 60-year-old woman with Cushing's syndrome secondary to adrenocortical carcinoma with liver metastasis, treated with a multimodal approach including surgery, radiotherapy, and systemic management with mitotane. Conclusion: This case significantly contributes to the current care model in Colombia for these rare neoplasms and proposes an integrated treatment strategy based on prognostic factors identified in the histopathological study, in line with the latest global advances.

      Article visits 22 | PDF visits 18

      1. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress? World J Surg [Internet]. 2006;30(5):1658. Disponible en: https://doi.org/10.1007/s00268-005-0329-x
      2. Passman JE, Amjad W, Soegaard Ballester JM, Ginzberg SP, Wachtel H. Defining Optimal Management of Non-metastatic Adrenocortical Carcinoma. Ann Surg Oncol [Internet]. 2024;31(2):1097-1107. Disponible en: https://doi.org/10.1245/s10434-023-14533-w
      3. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer [Internet]. 1993;72(11):3145-3155. Disponible en: https://doi.org/10.1002/1097-0142(19931201)72:11<3145::aid-cncr2820721105>3.0.co;2-n
      4. Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol [Internet]. 2013;169(6):891-899. Disponible en: https://doi.org/10.1530/EJE-13-0519
      5. Alexander K, Katherine M, Daniel C, Yu-Ning W, G UR. Effects of Increased Cross-Sectional Imaging on the Diagnosis and Prognosis of Adrenocortical Carcinoma: Analysis of the National Cancer Database. Journal of Urology [Internet]. 2011;186(3):805-810. Disponible en: https://doi.org/10.1016/j.juro.2011.04.072
      6. Mihai R. Diagnosis, treatment and outcome of adrenocortical cancer. British Journal of Surgery [Internet]. 2015;102(4):291-306. Disponible en: https://doi.org/10.1002/bjs.9743
      7. Libé R, Huillard O. Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease. Cancer Treat Res Commun [Internet]. 2023;37:100759. Disponible en: https://doi.org/https://doi.org/10.1016/j.ctarc.2023.100759
      8. Libé R, Borget I, Ronchi CL, et al. Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Annals of Oncology [Internet]. 2015;26(10):2119-2125. Disponible en: https://doi.org/10.1093/annonc/mdv329
      9. Ng L, Libertino J. Adrenocortical Carcinoma: Diagnosis, Evaluation and Treatment. J Urol [Internet]. 2003;169:5-11. Disponible en: https://doi.org/10.1097/01.ju.0000030148.59051.35
      10. Libé R, Huillard O. Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease. Cancer Treat Res Commun [Internet]. 2023;37:100759. Disponible en: https://doi.org/10.1016/j.ctarc.2023.100759
      11. Schteingart DE. Adjuvant Mitotane Therapy of Adrenal Cancer-Use and Controversy. New England Journal of Medicine [Internet]. 2007;356(23):2415-2418. Disponible en: https://doi.org/10.1056/NEJMe078087
      12. Koch CA, Pacak K, Chrousos GP. The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors. J Clin Endocrinol Metab [Internet]. 2002;87(12):5367-5384. Disponible en: https://doi.org/10.1210/jc.2002-021069
      13. Zheng S, Cherniack AD, Dewal N, et al. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell [Internet]. 2016;29(5):723-736. Disponible en: https://doi.org/10.1016/j.ccell.2016.04.002
      14. Juhlin CC, Goh G, Healy JM, et al. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism [Internet]. 2015;100(3):E493-E502. Disponible en: https://doi.org/10.1210/JC.2014-3282
      15. Assié G, Letouzé E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet [Internet]. 2014;46(6):607-612. Disponible en: https://doi.org/10.1038/ng.2953
      16. Abiven G, Coste J, Groussin L, et al. Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients. J Clin Endocrinol Metab [Internet]. 2006;91(7):2650-2655. Disponible en: https://doi.org/10.1210/jc.2005-2730
      17. Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol [Internet]. 2018;179(4):G1-G46. Disponible en: https://doi.org/10.1530/EJE-18-0608
      18. McCarthy CJ, McDermott S, Blake MA. Adrenal Imaging: Magnetic Resonance Imaging and Computed Tomography. Front Horm Res [Internet]. 2016;45:55-69. Disponible en: https://doi.org/10.1159/000442313
      19. Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology [Internet]. 2020;31(11):1476-1490. Disponible en: https://doi.org/10.1016/j.annonc.2020.08.2099
      20. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. Cancer [Internet]. 2009;115(2):243-250. Disponible en: https://doi.org/https://doi.org/10.1002/cncr.24030
      21. Lughezzani G, Sun M, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: A North American validation. Eur J Cancer. [Internet] 2010;46(4):713-719. Disponible en: https://doi.org/10.1016/j.ejca.2009.12.007
      22. Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization. Journal of Clinical Oncology 2002;20(4):941-950. Disponible en: https://doi.org/10.1200/JCO.2002.20.4.941
      23. Vassilopoulou-Sellin R, Schultz P. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer [Internet]. 2001;92:1113-1121. Disponible en: https://doi.org/10.1002/1097-0142(20010901)92:5<1113::aid-cncr1428>3.0.co;2-i
      24. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg [Internet]. 2001;25(7):891-897. Disponible en: https://doi.org/10.1007/s00268-001-0047-y
      25. Schulick RD, Brennan MF. Long-Term Survival After Complete Resection and Repeat Resection in Patients With Adrenocortical Carcinoma. Ann Surg Oncol [Internet]. 1999;6(8):719-726. Disponible en: https://doi.org/10.1007/s10434-999-0719-7
      26. Gaujoux S, Mihai R, Carnaille B, et al. European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma. British Journal of Surgery [Internet]. 2017;104(4):358-376. Disponible en: https://doi.org/10.1002/bjs.10414
      27. Waszut U, Szyska P, Dworakowska D. Understanding mitotane mode of action. J Physiol Pharmacol. [Internet]. 2017;68:13-26. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28456766/ PMID: 28456766
      28. Terzolo M, Zaggia B, Allasino B, De Francia S. Practical treatment using mitotane for adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes [Internet]. 2014;21(3). Disponible en: https://journals.lww.com/co-endocrinology/fulltext/2014/06000/practical_treatment_using_mitotane_for.4.aspx
      29. Terzolo M, Fassnacht M, Perotti P, et al. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol [Internet]. 2023;11(10):720-730. Disponible en: https://doi.org/10.1016/S2213-8587(23)00193-6
      30. Kimpel O, Bedrose S, Megerle F, et al. Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study. Br J Cancer [Internet]. 2021;125(9):1233-1238. Disponible en: https://doi.org/10.1038/s41416-021-01513-8
      31. Else T, Kim AC, Sabolch A, et al. Adrenocortical Carcinoma. Endocr Rev [Internet]. 2014;35(2):282-326. Disponible en: https://doi.org/10.1210/er.2013-1029
      32. Polat B, Fassnacht M, Pfreundner L, et al. Radiotherapy in adrenocortical carcinoma. Cancer [Internet]. 2009;115(13):2816-2823. Disponible en: https://doi.org/10.1002/cncr.24331
      33. Paragliola RM, Corsello A, Locantore P, Papi G, Pontecorvi A, Corsello SM. Medical Approaches in Adrenocortical Carcinoma. Biomedicines [Internet]. 2020;8(12):1-18. Disponible en: https://doi.org/10.3390/BIOMEDICINES8120551
      34. Fassnacht M, Terzolo M, Allolio B, et al. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine [Internet]. 2012;366(23):2189-2197. Disponible en: https://doi.org/10.1056/NEJMoa1200966
      35. Raj N, Zheng Y, Kelly V, et al. PD-1 Blockade in Advanced Adrenocortical Carcinoma. Journal of Clinical Oncology [Internet]. 2019;38(1):71-80. Disponible en: https://doi.org/10.1200/JCO.19.01586
      36. Habra MA, Stephen B, Campbell M, et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer [Internet]. 2019;7(1):253. Disponible en: https://doi.org/10.1186/s40425-019-0722-x
      37. Naing A, Meric-Bernstam F, Stephen B, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer [Internet]. 2020;8(1):e000347. Disponible en: https://doi.org/10.1136/jitc-2019-000347
      38. Chukkalore D, MacDougall K, Master V, Bilen MA, Nazha B. Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches. Oncologist [Internet]. February 21, 2024:oyae029. Disponible en: https://doi.org/10.1093/oncolo/oyae029

      Information

      Directories and indexers
      Google Scholar profile

      QR code

      Keywords

      Most read in the last 30 days

      Current Issue

      Sistema OJS 3.4.0.7 - Metabiblioteca |